<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336894">
  <stage>Registered</stage>
  <submitdate>5/05/2011</submitdate>
  <approvaldate>5/05/2011</approvaldate>
  <actrnumber>ACTRN12611000466943</actrnumber>
  <trial_identification>
    <studytitle>The dose effects of butyrylated starch in patients with familial adenomatous polyposis.</studytitle>
    <scientifictitle>A pilot study to determine the optimal dose of esterified butyrate in patients with familial adenomatous polyposis</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>None</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>familial adenomatous polyposis</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A 3 x 3 double blind crossover study examining butyrylated high amylose maize starch at 3 dose rates (a) 5 g/d (b) 20 g/d (c) 40 g/d.  There are 3 intervention periods of 14 days with a 7 day 'wash out' period between each intervention.  The starch is to be ingested orally by way of combination (starch plus long life milk).</interventions>
    <comparator>The butyrylated high amylose maize starch will be compared at 3 different doses (5 g/d, 20 g/d and 40 g/d).</comparator>
    <control>Dose comparison</control>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To quantify the release of butyrate in the colon.  Butyrate concentrations in faecal samples will be analysed using standard distillation procedures and gas chromatography.</outcome>
      <timepoint>At the beginning and end of each 14 day test period.</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>To determine the effects of consumption of the 3 doses of butyrylated high amylose maize starch on FAP patients' gastrointestinal quality of life using a validated assessement tool for evaluating the quality of life and distress for gastrointestinal symptoms (Eypasch et al., 1995 Gastrointestinal quality of life index: development, validation and application of a new instrument; British Journal of Surgery, 82, 216-222.)</outcome>
      <timepoint>At baseline and the end of each test period.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To examine the normal diet of FAP patients using repeated 24 hour diet diaries which will be collected for 2 weekdays and 1 weekend day.</outcome>
      <timepoint>At baseline and during the 2 washout periods.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>1. Age 18-75 years, male or female.
2. Generally in good health.
3. Patients with familial adenomatous polyposis with either ileorectal anastomosis or pouches.
4. Available for the duration of the study.
5. Willing to compy with faecal sample collection requirements.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>1. Intolerance to high-fibre products
2. Reported lactating, pregnant or wish to become pregnant during the study.  If the volunteer becomes pregnant during the trial they will be withdrawn.
3. Person considered by the investigator to be unwilling, unlikely or unable to comprehend or comply with the study protocol and restrictions.
4. Recent or planned sureveillance endoscopy +/- bowel preparation within the trial period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Allocation is not concealed</concealment>
    <sequence>Computerised sequence generator</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint>Safety</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate>14/01/2011</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>12</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Commonwealth Scientific and Industrial Research Organisation (CSIRO) Preventative Health National Research Flagship</primarysponsorname>
    <primarysponsoraddress>PO Box 10041
Adelaide SA 5000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Commonwealth Scientific and Industrial Research Organisation (CSIRO) Preventative Health National Research Flagship</fundingname>
      <fundingaddress>PO Box 10041
Adelaide SA 5000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The objectives of this pilot study are to determine the extent to which large bowel bacteria are capable of releasing esterified butyrate in FAP patients and to determine the acceptability of butyrylated high amylose maize starch in this participant group.  This study will consist of three double blinded randomised cross over studies and the objectives will be determined by feeding 3 different doses of the butyrylated high amylose maize starch to FAP patients and measuring butyrate levels in their faeces.  This study will provide information on the optimal dose for FAP patients to release esterified butyrate which will be used in a major clinical trial.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Southern Adelaide Flinders Clinical Human Research Ethics Committee</ethicname>
      <ethicaddress>Human Research Ethics Department
Room 2A/221 Level 2
Flinders Medical Centre
3 Flinders Drive 
Bedford Park SA 5042</ethicaddress>
      <ethicapprovaldate>13/07/2010</ethicapprovaldate>
      <hrec>1/10/0138</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>CSIRO Food and Nutritional Sciences Human Research Ethics Committee</ethicname>
      <ethicaddress>Po Box 10041
Adelaide SA 5000</ethicaddress>
      <ethicapprovaldate>29/07/2010</ethicapprovaldate>
      <hrec>10/15</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Melbourne Health</ethicname>
      <ethicaddress>PO Royal Melbourne Hospital
Parkville Victoria 3050</ethicaddress>
      <ethicapprovaldate />
      <hrec>2011.040</hrec>
      <ethicsubmitdate>25/03/2011</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Julie Clarke</name>
      <address>CSIRO Food and Nutritional Sciences
PO Box 10041
Adelaide SA 5000</address>
      <phone>+61 8 8303 8925</phone>
      <fax />
      <email>julie.clarke@csiro.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jessica Southwood</name>
      <address>CSIRO Food and Nutritional Sciences
PO Box 10041
Adelaide SA 5000</address>
      <phone>+61 8 8303 8927</phone>
      <fax />
      <email>jessica.southwood@csiro.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>